OKYO Pharma reports share acquisition by executive chairman and progress on urcosimod for neuropathic corneal pain treatment.
Quiver AI Summary
OKYO Pharma Limited, an ophthalmology-focused biopharmaceutical company, has announced that Gabriele Cerrone, Executive Chairman, through Panetta Partners Limited, has acquired over 27,000 of the company's ordinary shares, bringing his total stake to over 10.4 million shares. The company is developing urcosimod, a novel drug designed to treat neuropathic corneal pain, an ocular condition currently without an FDA-approved therapy. Urcosimod, a lipid-conjugated chemerin peptide agonist, has shown promise in reducing inflammation and pain in preclinical models and completed a randomized Phase 2 trial for treating neuropathic corneal pain. OKYO Pharma is also focused on innovative therapies for dry eye disease and continues to advance its clinical programs, with its shares traded on the NASDAQ Capital Market.
Potential Positives
- Gabriele Cerrone, the Executive Chairman, has increased his investment in OKYO Pharma, acquiring an additional 27,051 shares, indicating strong personal confidence in the company’s future.
- Urcosimod, the company's key drug candidate, demonstrated clear statistical significance in a completed Phase 2 trial for treating dry eye disease, which may bolster investor confidence and support further development efforts.
- The successful completion of the Phase 2 trial for neuropathic corneal pain positions OKYO Pharma as a potential leader in a market with no current FDA-approved therapies, highlighting the company's innovative approach in ophthalmology.
Potential Negatives
- Insider acquisition of shares by the Executive Chairman suggests potential conflict of interest or lack of investor confidence, raising concerns about governance.
- Despite promising results in Phase 2 trials, the drug urcosimod remains unapproved by the FDA, indicating significant regulatory hurdles ahead.
- The press release lacks detailed information on the outcomes of the completed Phase 2 trial for neuropathic corneal pain, leaving stakeholders uncertain about effectiveness and next steps.
FAQ
What is OKYO Pharma focused on?
OKYO Pharma is focused on developing innovative therapies for neuropathic corneal pain and dry eye disease.
What recent acquisition did Gabriele Cerrone make?
Gabriele Cerrone acquired 27,051 ordinary shares of OKYO Pharma, increasing his total holding to 10,491,746 shares.
What is urcosimod used for?
Urcosimod is being developed to treat neuropathic corneal pain, a condition characterized by severe nerve-related pain.
What distinguishes urcosimod from other therapies?
Urcosimod is a long-acting drug candidate designed to enhance efficacy through a lipid anchor, improving treatment outcomes.
What were the results of the Phase 2 trial for urcosimod?
The Phase 2 trial for urcosimod showed clear statistical significance in multiple endpoints for treating dry eye disease and neuropathic corneal pain.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$OKYO Hedge Fund Activity
We have seen 4 institutional investors add shares of $OKYO stock to their portfolio, and 4 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DAUNTLESS INVESTMENT GROUP, LLC removed 313,732 shares (-11.5%) from their portfolio in Q3 2025, for an estimated $627,464
- NORTHERN TRUST CORP added 57,158 shares (+inf%) to their portfolio in Q3 2025, for an estimated $114,316
- RENAISSANCE TECHNOLOGIES LLC added 41,200 shares (+inf%) to their portfolio in Q3 2025, for an estimated $82,400
- FNY INVESTMENT ADVISERS, LLC removed 20,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $51,400
- CITADEL ADVISORS LLC added 15,355 shares (+inf%) to their portfolio in Q3 2025, for an estimated $30,710
- OSAIC HOLDINGS, INC. added 152 shares (+inf%) to their portfolio in Q3 2025, for an estimated $304
- UBS GROUP AG removed 115 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $230
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$OKYO Analyst Ratings
Wall Street analysts have issued reports on $OKYO in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 09/23/2025
To track analyst ratings and price targets for $OKYO, check out Quiver Quantitative's $OKYO forecast page.
Full Release
LONDON and NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO ), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, today announces that Panetta Partners Limited, an entity in which Gabriele Cerrone, Executive Chairman has a beneficial interest, has acquired 27,051 of the Company’s ordinary shares on NASDAQ, bringing his total holding to 10,491,746 shares.
About Urcosimod (Formerly called OK-101)
Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response, as well as on neurons and glial cells in the dorsal root ganglion. Urcosimod was developed using a membrane-anchored-peptide technology to produce a novel long-acting drug candidate for treating ocular diseases. Urcosimod has been shown to produce anti-inflammatory and pain-reducing activities in mouse models of dry eye disease and corneal neuropathic pain, respectively, and is designed to combat washout through the inclusion of the lipid anchor built into the drug molecule to potentially enhance the efficacy of urcosimod within the ocular environment. Urcosimod showed clear statistical significance in multiple endpoints in a 240-patient completed Phase 2, multi-center, double-masked, placebo-controlled trial to treat dry eye disease, and just completed a randomized, placebo-controlled, double-masked Phase 2 trial of urcosimod to treat neuropathic corneal pain.
About OKYO
OKYO Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain and dry eye disease, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and dry eye disease. A Phase 2 trial of urcosimod to treat neuropathic corneal pain patients was just completed by OKYO.
For further information, please visit www.okyopharma.com .
Inquiries:
|
Business Development & Investor Relations |
Paul Spencer |
+44 (0)20 7495 2379 |
